Home > Healthcare > Medical Devices > Diagnostic Devices > ovarian cancer diagnostic market
Get a free sample of Ovarian Cancer Diagnostic Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Ovarian Cancer Diagnostic Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Advances in medical imaging, molecular biology, and genetic testing have revolutionized ovarian cancer diagnostics. High-resolution imaging modalities, such as MRI and PET-CT scans, provide detailed visualization of ovarian tumors and metastases, aiding in accurate diagnosis and staging.
Instruments/analyzers segment garnered USD 965.7 million in 2023 and is set to gain traction by 2032, driven by technological advancements and growing awareness about the importance of early detection and screening for ovarian cancer.
Global ovarian cancer diagnostic industry was valued at around USD 1.54 billion in 2023 and is estimated to reach over USD 2.71 billion by 2032, driven by increasing incidences of ovarian cancer worldwide.
Abbott Laboratories, Agilent Technologies, Canon Medical Systems Corporation, Danaher Corporation, F. Hoffmann-La Roche Ltd., Fujirebio Diagnostics, GE HealthCare Technologies Inc., Illumina Inc., Myriad Genetics, Philips Healthcare, Positron Corporation are some of the major industry contenders.
North America ovarian cancer diagnostic industry accounted for USD 624.4 million in 2023 and is predicted to witness substantial growth through 2032, driven by an advanced healthcare infrastructure and high levels of awareness regarding the importance of early cancer detection.